A yearly injection such as Lenacapavir could help overcome barriers to PrEP accessibility by increasing its uptake and making ...
Like most prescribed medications, all three brands PrEP brands feature side effects. Here's how to prepare for them.
A once-yearly intramuscular lenacapavir (Sunlenca) injection was safe and well-tolerated and had higher median levels of ...
March is a significant month for women's health, observing International Women's Day and National Women's HIV/AIDS Awareness ...
Pre-exposure prophylaxis (PrEP) is the advent of antiretroviral treatment use for people at increased risk of acquiring HIV-1 ...
A team of pharmaceutical researchers at biopharma company Gilead Sciences has announced that a reformulation of its HIV ...
Cabotegravir was found to prevent HIV acquisition as a monotherapy pre-exposure prophylaxis (PrEP) and to treat HIV as a ...
Children exposed to antiretroviral (ARV) therapy in utero and not exposed to HIV showed no difference in language development at 5 years of age compared with unexposed children, based on new data from ...
Gilead Sciences announced a significant milestone: the U.S. FDA accepted their New Drug Applications (NDAs) for lenacapavir ...